JP7854946B2 - 核酸人工ミニプロテオームライブラリー - Google Patents

核酸人工ミニプロテオームライブラリー

Info

Publication number
JP7854946B2
JP7854946B2 JP2022573214A JP2022573214A JP7854946B2 JP 7854946 B2 JP7854946 B2 JP 7854946B2 JP 2022573214 A JP2022573214 A JP 2022573214A JP 2022573214 A JP2022573214 A JP 2022573214A JP 7854946 B2 JP7854946 B2 JP 7854946B2
Authority
JP
Japan
Prior art keywords
rna
puromycin
polypeptide
tagged
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022573214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528805A5 (cg-RX-API-DMAC10.html
JP2023528805A (ja
Inventor
エドワード エフ. フリッチュ,
Original Assignee
ディオニス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディオニス セラピューティクス インコーポレイテッド filed Critical ディオニス セラピューティクス インコーポレイテッド
Publication of JP2023528805A publication Critical patent/JP2023528805A/ja
Publication of JP2023528805A5 publication Critical patent/JP2023528805A5/ja
Priority to JP2026070113A priority Critical patent/JP2026117232A/ja
Application granted granted Critical
Publication of JP7854946B2 publication Critical patent/JP7854946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022573214A 2020-05-26 2021-05-26 核酸人工ミニプロテオームライブラリー Active JP7854946B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026070113A JP2026117232A (ja) 2020-05-26 2026-04-21 核酸人工ミニプロテオームライブラリー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063030056P 2020-05-26 2020-05-26
US63/030,056 2020-05-26
PCT/US2021/034131 WO2021242793A2 (en) 2020-05-26 2021-05-26 Nucleic acid artificial mini-proteome libraries

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026070113A Division JP2026117232A (ja) 2020-05-26 2026-04-21 核酸人工ミニプロテオームライブラリー

Publications (3)

Publication Number Publication Date
JP2023528805A JP2023528805A (ja) 2023-07-06
JP2023528805A5 JP2023528805A5 (cg-RX-API-DMAC10.html) 2024-06-04
JP7854946B2 true JP7854946B2 (ja) 2026-05-07

Family

ID=76859704

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022573214A Active JP7854946B2 (ja) 2020-05-26 2021-05-26 核酸人工ミニプロテオームライブラリー
JP2026070113A Pending JP2026117232A (ja) 2020-05-26 2026-04-21 核酸人工ミニプロテオームライブラリー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026070113A Pending JP2026117232A (ja) 2020-05-26 2026-04-21 核酸人工ミニプロテオームライブラリー

Country Status (8)

Country Link
US (1) US20230203477A1 (cg-RX-API-DMAC10.html)
EP (1) EP4158014A2 (cg-RX-API-DMAC10.html)
JP (2) JP7854946B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230029673A (cg-RX-API-DMAC10.html)
CN (1) CN116249774A (cg-RX-API-DMAC10.html)
AU (1) AU2021280261A1 (cg-RX-API-DMAC10.html)
CA (1) CA3185387A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021242793A2 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023034901A1 (en) 2021-09-01 2023-03-09 The Broad Institute, Inc. Tumor avatar vaccine compositions and uses thereof
US12112833B2 (en) 2020-02-04 2024-10-08 10X Genomics, Inc. Systems and methods for index hopping filtering
US12168801B1 (en) * 2020-07-02 2024-12-17 10X Genomics, Inc. Hybrid/capture probe designs for full-length cDNA
US12580044B1 (en) 2020-09-02 2026-03-17 10X Genomics, Inc. Systems and methods for identifying cells that are antigen-specific for an immunogenic feature
US20250144198A1 (en) * 2021-08-16 2025-05-08 Duke University Next generation vaccines comprising antigenic libraries and methods of making and using same
WO2023076733A1 (en) * 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
EP4594488A1 (en) * 2022-09-29 2025-08-06 Twist Bioscience Corporation Libraries for rna enrichment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522091A (ja) 1998-08-17 2002-07-23 フィロス インク. 3’非翻訳領域を欠損する核酸を生成して細胞rna蛋白質融合体形成を最適化する方法
WO2005035751A1 (ja) 2003-10-15 2005-04-21 Keio University 高機能性タンパク質の迅速、高効率な選択法、それによって得られる高機能性タンパク質、およびその製造方法と利用方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4226859A (en) 1979-06-07 1980-10-07 Velsicol Chemical Corporation Pyridyl esters of N-alkylidene-substituted phosphor- and phosphonamidic acids
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
ES2243937T3 (es) 1994-04-29 2005-12-01 Baxter Healthcare S.A. Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños.
US5705190A (en) 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US7255862B1 (en) 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs
WO1999014354A1 (en) 1997-09-19 1999-03-25 The Trustees Of The University Of The Pennsylvania Methods and vector constructs useful for production of recombinant aav
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
WO2000006717A2 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
EP1101490B1 (en) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
US6955808B2 (en) 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
ES2376454T3 (es) 2000-12-22 2012-03-14 Grad, Carole, Legal Representative Of Howard, Kaplan Librer�?as de expresión en fago de fragmentos vh humanos.
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
EP2397490B1 (en) 2004-07-16 2013-09-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV
EP2573185A3 (en) 2005-02-16 2013-06-05 Lentigen Corporation Lentiviral vectors and their use
JP2011512326A (ja) 2007-12-31 2011-04-21 ナノコア セラピューティクス,インコーポレイテッド 心不全の治療用のrna干渉
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
WO2018213803A1 (en) * 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
WO2020018461A1 (en) * 2018-07-16 2020-01-23 The University Of Virginia Patent Foundation Compositions and methods of diagnosis and treatment for neurological diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522091A (ja) 1998-08-17 2002-07-23 フィロス インク. 3’非翻訳領域を欠損する核酸を生成して細胞rna蛋白質融合体形成を最適化する方法
WO2005035751A1 (ja) 2003-10-15 2005-04-21 Keio University 高機能性タンパク質の迅速、高効率な選択法、それによって得られる高機能性タンパク質、およびその製造方法と利用方法

Also Published As

Publication number Publication date
KR20230029673A (ko) 2023-03-03
EP4158014A2 (en) 2023-04-05
CN116249774A (zh) 2023-06-09
JP2026117232A (ja) 2026-07-14
US20230203477A1 (en) 2023-06-29
WO2021242793A2 (en) 2021-12-02
WO2021242793A3 (en) 2022-02-24
JP2023528805A (ja) 2023-07-06
AU2021280261A1 (en) 2023-01-19
CA3185387A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
US20230203477A1 (en) Nucleic acid artificial mini-proteome libraries
JP5016614B2 (ja) キメラアデノウイルスベクター
CN111492056B (zh) 用于细胞的遗传修饰的非整合型dna载体
JP7034080B2 (ja) ヒトflt3lを発現する組換えmvaまたはmvaδe3lおよび固形腫瘍に対する免疫療法薬としてのそれらの使用
US12247214B2 (en) Vaccinia viral vectors encoding chimeric virus like particles
KR20160030317A (ko) 유전자 조작된 항체 유전자 발현 카세트를 갖는 미니서클 dna 재조합 모 플라스미드, 상기 발현 카세트를 갖는 미니서클 dna 및 용도
CN110923255B (zh) 靶向bcma和cd19嵌合抗原受体及其用途
CN105246496A (zh) 用于癌症免疫治疗的靶向肾母细胞瘤基因wt-1的基于沙门菌的载体
AU2016205208A1 (en) Methods and compositions for ebola virus vaccination
CN111349645A (zh) 一种提高非整合减毒李斯特菌疫苗安全性的方法
CN115989321B (zh) 病毒制剂、用于配制病毒制剂的溶液及其用途
CN116199787A (zh) 一种基于uPA的GFD结构域构建的嵌合抗原受体免疫细胞制备及其应用
CN105585637B (zh) 基于il-12稳定膜表达的肿瘤治疗剂及其制法和用途
CN117004579B (zh) 重组溶瘤牛痘病毒及其应用
WO2023076733A1 (en) Biologically selected nucleic acid artificial mini-proteome libraries
WO2024026274A2 (en) Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc)
WO2023217192A1 (zh) 基于msln前体蛋白构建的嵌合抗原受体免疫细胞制备及其应用
WO2017117890A1 (zh) Il-12/cd107a融合蛋白及其制法和用途
CN115819614A (zh) 一种基于il34的嵌合抗原受体免疫细胞制备及其应用
JP2025534300A (ja) Ctaワクチンカセット
CN121873266A (zh) 一种增强肿瘤疫苗免疫原性的嵌合多肽及其制备方法和用途
WO2004050112A1 (en) Intratumor administration of heat shock protein and its combination tumor therapy with cell toxin
HK1226097B (en) Rna transcription vector and uses thereof
CN104491852A (zh) 以粘蛋白1和生存素为靶点的肿瘤dna疫苗及病毒载体疫苗
MXPA02003986A (en) Chimeric immunogenic compositions and nucleic acids encoding them

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240527

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260323

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260421

R150 Certificate of patent or registration of utility model

Ref document number: 7854946

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150